A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Recruiting · Phase 1 · NCT05981703
Conditions: Advanced Solid Tumor, Solid Tumor
At a glance
- Research payments reported, 2025
- $1.9M
- U.S. investigators named
- 5
- Sites paid
- 9
- Planned or actual enrollment
- 337
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BGB-26808 (drug), Tislelizumab (drug), Chemotherapy (drug)
- Dates
- Started 2023-09-21; completion 2029-02-28
- Results posted
- Not yet
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $1.9M in research payments for this study in 2025 (86 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Gilberto Lopes, MD Medical Oncology · Miami, FL
- Martin E. Gutierrez, MD Medical Oncology · Hackensack, NJ
- Dan Feng Medical Oncology · New York, NY
- Aung Naing, MD Internal Medicine · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $504,668
- Ut MD Anderson Cancer Center $262,698
- Hackensack University Medical Center, NJ $218,387
- Yale Cancer Center $208,512
- Sylvester Cancer Center $187,096
- University of Miami $179,222
- Icahn School of Medicine at Mount Sinai $176,261
- Mount Sinai Medical Center of Florida, Inc, FL $87,424
- Yale University $82,436
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.